Evaluation of Antioxidant Status and Serum Lipoprotein(a) in Coronary Heart Diseases
Advances in Biochemistry
Volume 2, Issue 1, February 2014, Pages: 1-8
Received: Nov. 27, 2013; Published: Jan. 20, 2014
Views 3562      Downloads 124
Authors
Sudeep. R. Lokapure, Department of Biochemistry,Goa Medical college,Bambolim-Goa
Jano Zore, Department of Biochemistry,Goa Medical college,Bambolim-Goa
Kavitha. Y. Ullikashi, Subject Matter Specialist (Home science), Krishi vigyan kendra,Hagari,Bellary,Karnataka
Chitra Dhume, Department of Biochemistry,Goa Medical college,Bambolim-Goa
Article Tools
PDF
Follow on us
Abstract
Coronary heart disease (CHD) has become the most important cause of premature morbidity and mortality. The chief risk factors for CHD includes Smoking, Hypertension, Diabetes mellitus, Hypercholesterolemia, Low high density lipoprotein, Obesity, Mental stress, Type A personality and Genetic factors. Lipoprotein (a) has been established as a strong independent risk factor for premature CHD, which is highly thrombogenic and antifibrinolytic which begins to block the arteries much earlier than other risk factors. This study is planned to determine the antioxidant status and to estimate Serum lipoprotein (a) levels in patients of CHD and in patients with risk factors for CHD. Among all the patients, majority of patients belongs to upper and middle class. In routine investigations an increase in serum cholesterol, serum LDL, TC/HDL and LDL/HDL ratio were seen in all five groups including MI, HT, DM, Smokers and obesity cases, which were statistically significant. Serum Triglycerides were increased in MI, DM, Smokers and obesity cases, which were statistically significant, where as significant increase was not seen in HT cases. Serum VLDL showed a statistically significant increase in MI, Smokers and obesity cases, where as significant increases was not seen in HT and DM cases. Blood glucose showed a significant increase in DM cases, where as no significant increase were seen in MI, HT, smokers and obesity cases. A statistically significant decrease in serum HDL were seen in all five groups including MI, HT, DM, Smokers and obesity cases. In special investigations, there is significant increase in MDA, Lipoprotein (a) levels and significant decrease of antioxidants such as blood glutathione, Serum vitamin E, vitamin C and vitamin A in cases of coronary heart diseases and also in cases with risk factors for Coronary heart diseases including hypertension, diabetes mellitus, smoking and obesity. Hence, it is therefore concluded that MDA, Lipoprotein (a) and antioxidants like glutathione, vitamin E, Vitamin C and Vitamin A, be evaluated as biochemical parameters for preclinical assessment of “at risk group” for Coronary heart diseases and for assessing and monitoring cases of Coronary heart diseases.
Keywords
Coronary Heart Diseases, Lipoprotein (A), MDA, Antioxidants
To cite this article
Sudeep. R. Lokapure, Jano Zore, Kavitha. Y. Ullikashi, Chitra Dhume, Evaluation of Antioxidant Status and Serum Lipoprotein(a) in Coronary Heart Diseases, Advances in Biochemistry. Vol. 2, No. 1, 2014, pp. 1-8. doi: 10.11648/j.ab.20140201.11
References
[1]
Assmann G.,Cullen P.,Schulte H.,The Miinister Heart Study(PROCAM):results of fallow-up at 8 years.Eur Heart Journal 1998; 19( Suppl A): A2-A11.
[2]
Boston A G.,Cupples L A.,Jenner J L.,Ordovas J M.,Seman L J.,Wilson P W.,Schaefer E J.,Castelli W P., Elevated plasma Lipoprotein (a) and Coronary heart disease in men aged 55 years and younger.A prospective study.JAMA 1996;276:544-548.
[3]
Harrison’s principle of Internal medicine,15th ed,2003.
[4]
Leo J S.,Carl D.,Jennifer L J.,Adriene C L.,Judith R M.,Peter W F M.,William P C.,Jose M O.,Ernst J S., Lipoprotein(a)-cholesterol and coronary heart disease in the Framingham heart study. Clin Chem 1999;45:1039-1046.
[5]
Matthias N.,Winfried M.,Heinrich W.,Is Lipoprotein(a) Cholesterol a significant indicator of cardiovascular risk?.Clin Chem 2000;46:436-437.
[6]
Mc Cord J M.,Oxygen derived free radicals in post-ischaemic tissue injury.N Eng J Med 1985;312:159.
[7]
P.S.M. 17th ed.Park JE, Park K,2003.
[8]
Practical clinical Biochemistry,5th ed,Varley 1980.
[9]
Rajasekhar D.,Saibaba KSS.,Srinivasa Rao PVLN., Latheef SAA.,Subramanyam G., Lipoprotein(a): Better assessor of Coronary heart disease risk in South Indian population.Ind J Clin Biochem2004;19(2):53-59.
[10]
Rath M.,Niendorf A.,Reblin T.,Dietel M.,Krebber HJ.,Beisiegel U.,Detection and quantification of Lipoprotein(a) in the arterial wall of 107 coronary bypass patients.Athersclerosis 1989;9:579-92.
[11]
Sarah H W.,Stehen P F.,Santica M M.,A Prospective case control study of Lipoprotein(a) levels and Apo(a) size and risk of coronary heart disease in Stanford five-city project participants.Arterioscler Thromb Vasc Biol 1997;17:239-245.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186